Retatrutide 10mg
Triple-agonist GLP-1/GIP/GCGR retatrutide at 10mg — the higher-concentration vial for sustained metabolic-research titration schedules.
Compound
At a glance
At a glance
- Concentration
- 10mg
- Purity
- 99.5%+
- Route
- Subcutaneous injection
- Storage
- Lyophilized: room temperature, desiccated. Reconstituted: 2–8°C, ≤30 days.
The 10mg high-dose vial of retatrutide provides extended supply for researchers conducting sustained triple-agonist metabolic protocols. The compound, triple GLP-1/GIP/GCGR mechanism, and research applications are identical to the 5mg formulation. This format is designed for researchers maintaining at higher weekly doses (8-12mg), offering superior per-milligram value and extended protocol duration from a single vial.
Reconstitute with 2-4ml bacteriostatic water. All dose-escalation guidelines (start at 1mg weekly, titrate over 4-week intervals), storage requirements (2-8C after reconstitution, -20C for long-term lyophilized storage), and administration protocols (once-weekly subcutaneous injection) follow the standard retatrutide parameters.
Retatrutide 10mg is supplied as a lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water (BAC water) before use in a research setting.
- Clean the BAC water vial stopper and the peptide vial stopper with an alcohol swab. Allow to dry.
- Draw the required volume of BAC water into a sterile syringe (typically 1–3 mL depending on target concentration).
- Angle the needle so the water runs down the inside wall of the peptide vial. Avoid dispensing directly onto the powder.
- Do not shake. Gently swirl or roll until fully dissolved. Vigorous shaking can denature peptides.
- Refrigerate reconstituted solution at 2–8°C. Most reconstituted peptides are stable 14–30 days depending on compound.
Target concentration determines drawing volume. For dosing math, consult the dosing math guide.
Independent lab verification
Research disclaimer
For research and laboratory use only. Not for human or veterinary consumption. Novo Pharma sells to qualified researchers of legal age and ships to Canadian addresses only. See disclaimer and terms.
Read the research
Reference articles from the lab covering this compound.
compound guides
Retatrutide: The Triple-Agonist That Outperforms Semaglutide & Tirzepatide
Retatrutide (LY3437943) triple-agonist guide: 24.2% weight loss in trials, outperforming semaglutide & tirzepatide. Mechanism, dosing & FDA timeline.
compound guides
Tirzepatide — A Complete Research Reference
Tirzepatide: a dual GIP/GLP-1 receptor agonist with FDA-approved indications in type 2 diabetes and chronic weight management. Structure, pharmacology, SURPASS and SURMOUNT trial data, safety, and open questions.
blog
The Semaglutide-to-Retatrutide Shift: A Researcher's Reading List
Triple-agonist peptides are the next generation beyond semaglutide and tirzepatide. Here's the research timeline, mechanism differences, and what remains unknown.
